Add to ORKGHammerhead ribozymes are small RNA molecules that can be designed to specifically recognize and cleave a target RNA. A single ribozyme can theoretically act in a catalytic manner thus cleaving more than one molecule of its target RNA. Because of their sequence specificity, ribozymes are being developed as therapeutic agents to eliminate unwanted cellular and viral RNAs. Ribozymes are being used to inhibit human immunodeficiency virus type-1 (HIV-1) replication. Promising results have been obtained by several groups using ribozymes targeted against various sites within the HIV-1 genome. This article reviews some of the factors relevant to the design of hammerhead ribozymes with a particular focus on their application in HIV-1 gene therapy. I
The limited efficacy of current therapeutic approaches for a number of socially relevant human disea...
Includes bibliographical references (pages [44]-45)Use of catalytic RNAs (ribozymes) as anti-viral t...
Using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that ef...
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are still a scienti...
Approximately 40 million people are infected with HIV-1 and AIDS is the number one cause of death in...
RNA molecules with enzymatic activity (ribozymes) targeted to the genome of HIV-1 were developed and...
RNA molecules with enzymatic activity (ribozymes) targeted to the genome of HIV-1 were developed and...
grantor: University of TorontoRibozymes are small, catalytic RNA molecules which possess e...
Ribozymes are catalytic RNAs that offer several advantages as specific therapeutic genes against hum...
Approximately 40 million people are infected with HIV-1 and AIDS is the number one cause of death in...
A hammerhead ribozyme targeted against the HIV-1 env coding region was expressed as part of the anti...
The length requirements of the antisense portion of hammerhead ribozymes for efficacy in living cell...
Ribozymes are catalytic RNA molecules that recognize their target RNA in a highly sequence-specific ...
HIV-1 is the causative agent in AIDS, the world's fourth most frequent cause of death. HIV is a retr...
AbstractRibozymes are catalytic RNAs that offer several advantages as specific therapeutic genes aga...
The limited efficacy of current therapeutic approaches for a number of socially relevant human disea...
Includes bibliographical references (pages [44]-45)Use of catalytic RNAs (ribozymes) as anti-viral t...
Using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that ef...
Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are still a scienti...
Approximately 40 million people are infected with HIV-1 and AIDS is the number one cause of death in...
RNA molecules with enzymatic activity (ribozymes) targeted to the genome of HIV-1 were developed and...
RNA molecules with enzymatic activity (ribozymes) targeted to the genome of HIV-1 were developed and...
grantor: University of TorontoRibozymes are small, catalytic RNA molecules which possess e...
Ribozymes are catalytic RNAs that offer several advantages as specific therapeutic genes against hum...
Approximately 40 million people are infected with HIV-1 and AIDS is the number one cause of death in...
A hammerhead ribozyme targeted against the HIV-1 env coding region was expressed as part of the anti...
The length requirements of the antisense portion of hammerhead ribozymes for efficacy in living cell...
Ribozymes are catalytic RNA molecules that recognize their target RNA in a highly sequence-specific ...
HIV-1 is the causative agent in AIDS, the world's fourth most frequent cause of death. HIV is a retr...
AbstractRibozymes are catalytic RNAs that offer several advantages as specific therapeutic genes aga...
The limited efficacy of current therapeutic approaches for a number of socially relevant human disea...
Includes bibliographical references (pages [44]-45)Use of catalytic RNAs (ribozymes) as anti-viral t...
Using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that ef...